Page last updated: 2024-11-05

3-(5'-hydroxymethyl-2'-furyl)-1-benzylindazole and Cancer of Larynx

3-(5'-hydroxymethyl-2'-furyl)-1-benzylindazole has been researched along with Cancer of Larynx in 1 studies

3-(5'-hydroxymethyl-2'-furyl)-1-benzylindazole: antineoplastic; activates platelet guanylate cyclase; a radiosensitizing agent and guanylate cyclase activator; structure in first source
lificiguat : A member of the class of indazoles that is 1H-indazole which is substituted by a benzyl group at position 1 and a 5-(hydroxymethyl)-2-furyl group at position 3. It is an activator of soluble guanylate cyclase and inhibits platelet aggregation.

Research

Studies (1)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's1 (100.00)29.6817
2010's0 (0.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Moon, SY1
Chang, HW1
Roh, JL1
Kim, GC1
Choi, SH1
Lee, SW1
Cho, KJ1
Nam, SY1
Kim, SY1

Other Studies

1 other study available for 3-(5'-hydroxymethyl-2'-furyl)-1-benzylindazole and Cancer of Larynx

ArticleYear
Using YC-1 to overcome the radioresistance of hypoxic cancer cells.
    Oral oncology, 2009, Volume: 45, Issue:10

    Topics: Carcinoma, Squamous Cell; Cell Hypoxia; Cell Line, Tumor; Humans; Hypoxia-Inducible Factor 1, alpha

2009